Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

147.75
+3.422.37%
Post-market: 142.39-5.3600-3.63%19:52 EDT
Volume:567.40K
Turnover:82.97M
Market Cap:9.56B
PE:143.45
High:149.30
Open:143.26
Low:141.95
Close:144.33
52wk High:160.81
52wk Low:54.50
Shares:64.71M
Float Shares:63.17M
Volume Ratio:1.20
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.03
EPS(LYR):-2.0500
ROE:10.98%
ROA:4.55%
PB:11.36
PE(LYR):-72.07

Loading ...

Protagonist Therapeutics price target raised to $151 from $119 at Barclays

TIPRANKS
·
Jul 14

Analysts’ Top Healthcare Picks: HCA Healthcare (HCA), Protagonist Therapeutics (PTGX)

TIPRANKS
·
Jul 14

Will Icotyde’s Launch and Rusfertide’s Priority Review Change Protagonist Therapeutics’ (PTGX) Narrative

Simply Wall St.
·
Jul 10

Movement Alert|Protagonist Therapeutics Rises 6.35% in Regular Trading, Truist Raises Price Target to $145

Market Focus
·
Jul 08

Protagonist Therapeutics is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 07

Protagonist Therapeutics Inc : Truist Securities Raises Target Price to $145 from $121

THOMSON REUTERS
·
Jul 07

Truist Raises Price Target on Protagonist Therapeutics to $145 From $121, Keeps Buy Rating

MT Newswires Live
·
Jul 07

The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following Rusfertide Review Optimism And New Hires – Learn Why

Simply Wall St.
·
Jul 02

Protagonist Therapeutics Grants Inducement Awards for 8,650 Share Options, 2,275 Rsus to New Hires

Reuters
·
Jul 02

Medicare Coverage Could Put These Obesity Drug Stocks In Focus

Simply Wall St.
·
Jun 30

Insider Cashes In: Major Protagonist Therapeutics Stock Sale Shakes Up Investors

TIPRANKS
·
Jun 26

Protagonist Therapeutics Director William D. Waddill Disposes of Common Shares Worth $1.06 Million

Reuters
·
Jun 26

Protagonist Therapeutics Stockholders Approve Directors and Incentive Plan

TIPRANKS
·
Jun 19

Protagonist Therapeutics shareholders approve 2026 equity incentive plan at annual meeting

Reuters
·
Jun 19

Protagonist Therapeutics grants inducement equity awards for 18,700 shares at $112.46 strike

Reuters
·
Jun 17

Top Protagonist Therapeutics Insider Makes a Major Move With His Shares

TIPRANKS
·
Jun 12

Protagonist Therapeutics director William D. Waddill disposes of USD 969,120 in common shares

Reuters
·
Jun 12

Could New Rusfertide Data Presentations Subtly Reframe Protagonist Therapeutics' (PTGX) Core Investment Narrative?

Simply Wall St.
·
Jun 04

Protagonist Therapeutics director William D. Waddill disposes of 9,000 common shares worth $896,760

Reuters
·
Jun 02

Protagonist Therapeutics CEO Patel to speak at Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 28